REXAHN PHARMACEUTICALS DEF 14A 6-2-2006

Company

Opus Genetics, Inc.

Filed

May 15, 2006

Period of Report

June 2, 2006

Accession Number

0001140361-06-007441

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →